TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04550481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Ultrasonographic Elastography
Description: Undergo transient elastography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo PDFF MRE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PDFF MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Density Fat Fraction
Description: Undergo PDFF MRI/MRE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04982029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 100 MG/ML [Epidiolex]
Description: 600mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05144152

Intervention type: DIAGNOSTIC_TEST
Intervention: M3
Description: A panel of four bacterial gene markers (Fn, m3, Ch and Bc)

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: faecal immunochemical test
Study: NCT05484401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200Mg Oral Cap
Description: 2 x 200mg Liquid Capsules once in 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200Mg Oral Tablet
Description: 2 x 200mg Tablets once in 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid Capsule
Description: 2 x Liquid Capsules once in 12 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Liquid Capsule
Description: 2 x Liquid Capsules once in 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: 2 x Tablets once in 12 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: 2 x Tablets once in 12 hours
Study: NCT06359964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal Biopsy without antibiotics prophylaxis
Description: Transperineal Biopsy without antibiotics prophylaxis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal Biopsy with antibiotics prophylaxis
Description: Transperineal Biopsy with antibiotics prophylaxis
Study: NCT06418932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UrgoK2 / UrgoK2 Lite
Description: Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controll
Description: Administration of parenteral diuretics only
Study: NCT04977830

Intervention type: DEVICE
Group type: OTHER
Intervention: Xenon-129
Description: Patients will undergo a hyperpolarized MRI with administered Xenon gas
Study: NCT04920162

Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen into patients who had skin diseases
Description: Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
Study: NCT06056063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halcyon 4.0
Description: This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
Study: NCT05446376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate PET/CT
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Study: NCT06156631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH-ExMAMI
Description: The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
Study: NCT06399276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
Study: NCT05354206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology assessment - corticospinal tract
Description: Kinematics and cortical spinal motor excitability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology assessment - reticulospinal tract
Description: Kinematics and reticular spinal motor excitability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with some stimulation
Description: Motor task combined with real or sham stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with some stimulation
Description: Motor task combined with real or sham stimulation
Study: NCT05854745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBB Virtual Training
Description: HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBB In-person Training
Description: HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
Study: NCT05595161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Bodies
Description: The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
Study: NCT06183229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloferon
Description: Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
Study: NCT04332172

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General information
Description: General information related to pregnancy is provided electronically.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information
Description: General information related to pregnancy is provided electronically.
Study: NCT06000007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app
Description: 2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
Study: NCT06415669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: 100 mg/m2, day 1, day 8, every 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg or 1200mg, the first day, every 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: 250mg once a day for 5 consecutive days and discontinue for 2 days
Study: NCT06462469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
Study: NCT06214780

Intervention type: DEVICE
Intervention: advanced hybrid closed-loop
Description: An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions.
Study: NCT06095362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
Study: NCT04332172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote online booster sessions
Description: Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
Study: NCT04846075

Intervention type: BEHAVIORAL
Intervention: Ramadan fasting, praying, and welfare for poor
Description: Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
Study: NCT04332172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
Study: NCT05561686

Intervention type: DRUG
Intervention: Pyrotinib
Description: This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
Study: NCT04457323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
Study: NCT05448690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two different approaches
Description: Please refer to Groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-combined approach
Description: Either transnasal, transcranial or a staged approach
Study: NCT06018740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Balance Gummy
Description: Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
Study: NCT05433558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Rehabilitation
Description: Neuropsychological Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Rehabilitation
Description: Neuropsychological Rehabilitation
Study: NCT05430516

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04891549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band fixation
Description: Fracture fixation of the patella fracture with tension band.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: Fracture fixation of the patella fracture with a plate.
Study: NCT04955938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
Study: NCT05262894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extreme hypercapnia induced by ventilation insufficiency
Description: Re-breathing of gas by breathing into the simulated avalanche snow
Study: NCT06536868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
Study: NCT04955938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
Study: NCT04684797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual T-maze task
Description: Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
Study: NCT05010109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Functional Test
Description: Participate in 6 MWT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Functional Test
Description: Participate in 6 MWT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT
Study: NCT06536868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
Study: NCT05010109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Cardiac Stress Test
Description: Undergo stress test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Cardiac Stress Test
Description: Undergo stress test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT06536868

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: IMRT 30-45Gy/10-15f
Study: NCT06446973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 patients with meniscus tear
Description: Have meniscus pathologies in one or both knees confirmed by MRI.
Study: NCT06325774

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study: NCT06580821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucogingigval surgery
Description: Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mucogingigval surgery
Description: Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
Study: NCT04742738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution)- Stage 2
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study: NCT05044234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral